JP2020513808A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513808A5 JP2020513808A5 JP2019550715A JP2019550715A JP2020513808A5 JP 2020513808 A5 JP2020513808 A5 JP 2020513808A5 JP 2019550715 A JP2019550715 A JP 2019550715A JP 2019550715 A JP2019550715 A JP 2019550715A JP 2020513808 A5 JP2020513808 A5 JP 2020513808A5
- Authority
- JP
- Japan
- Prior art keywords
- box
- high mobility
- modified high
- mobility group
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100037907 High mobility group protein B1 Human genes 0.000 claims description 33
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 32
- 238000006467 substitution reaction Methods 0.000 claims description 30
- 102220491808 Cilia- and flagella-associated protein HOATZ_C45S_mutation Human genes 0.000 claims description 29
- 102220491845 Cilia- and flagella-associated protein HOATZ_C23S_mutation Human genes 0.000 claims description 20
- 102220491822 High mobility group protein B1_C106S_mutation Human genes 0.000 claims description 19
- 229920001184 polypeptide Polymers 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 108020004414 DNA Proteins 0.000 claims description 11
- 230000000813 microbial effect Effects 0.000 claims description 11
- 108091033319 polynucleotide Proteins 0.000 claims description 10
- 102000040430 polynucleotide Human genes 0.000 claims description 10
- 239000002157 polynucleotide Substances 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000000576 coating method Methods 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 241000588626 Acinetobacter baumannii Species 0.000 claims description 6
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 claims description 6
- 241000371430 Burkholderia cenocepacia Species 0.000 claims description 6
- 241000588914 Enterobacter Species 0.000 claims description 6
- 241000194031 Enterococcus faecium Species 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 241000606768 Haemophilus influenzae Species 0.000 claims description 6
- 241000588747 Klebsiella pneumoniae Species 0.000 claims description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 6
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 229940047650 haemophilus influenzae Drugs 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 230000032770 biofilm formation Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000004568 DNA-binding Effects 0.000 claims 1
- 102100022124 High mobility group protein B4 Human genes 0.000 description 3
- 101001045782 Homo sapiens High mobility group protein B4 Proteins 0.000 description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
- 102100022130 High mobility group protein B3 Human genes 0.000 description 2
- 101001045794 Homo sapiens High mobility group protein B3 Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 1
- 102100022128 High mobility group protein B2 Human genes 0.000 description 1
- 101001045791 Homo sapiens High mobility group protein B2 Proteins 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 102220236461 rs875989895 Human genes 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022194227A JP2023014389A (ja) | 2017-03-15 | 2022-12-05 | 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 |
| JP2025018512A JP2025065351A (ja) | 2017-03-15 | 2025-02-06 | 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 |
| JP2025119036A JP2025148518A (ja) | 2017-03-15 | 2025-07-15 | 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471834P | 2017-03-15 | 2017-03-15 | |
| US62/471,834 | 2017-03-15 | ||
| PCT/US2018/022508 WO2018170178A1 (en) | 2017-03-15 | 2018-03-14 | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022194227A Division JP2023014389A (ja) | 2017-03-15 | 2022-12-05 | 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020513808A JP2020513808A (ja) | 2020-05-21 |
| JP2020513808A5 true JP2020513808A5 (https=) | 2021-04-22 |
| JP7596069B2 JP7596069B2 (ja) | 2024-12-09 |
Family
ID=62025942
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550715A Active JP7596069B2 (ja) | 2017-03-15 | 2018-03-14 | 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 |
| JP2022194227A Pending JP2023014389A (ja) | 2017-03-15 | 2022-12-05 | 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 |
| JP2025018512A Pending JP2025065351A (ja) | 2017-03-15 | 2025-02-06 | 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 |
| JP2025119036A Pending JP2025148518A (ja) | 2017-03-15 | 2025-07-15 | 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022194227A Pending JP2023014389A (ja) | 2017-03-15 | 2022-12-05 | 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 |
| JP2025018512A Pending JP2025065351A (ja) | 2017-03-15 | 2025-02-06 | 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 |
| JP2025119036A Pending JP2025148518A (ja) | 2017-03-15 | 2025-07-15 | 付随する炎症のない細菌バイオフィルムの破壊のための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11746136B2 (https=) |
| EP (1) | EP3595445B1 (https=) |
| JP (4) | JP7596069B2 (https=) |
| AU (1) | AU2018236271B2 (https=) |
| CA (1) | CA3056088A1 (https=) |
| WO (1) | WO2018170178A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
| WO2017023863A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
| JP7661008B2 (ja) | 2017-01-04 | 2025-04-14 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | バイオフィルム関連障害の処置のための抗体断片 |
| US11564982B2 (en) | 2017-01-04 | 2023-01-31 | Research Institute At Nationwide Children's Hospital | DNABII vaccines and antibodies with enhanced activity |
| WO2018170178A1 (en) * | 2017-03-15 | 2018-09-20 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
| AU2019354829B2 (en) * | 2018-10-05 | 2025-04-17 | Research Institute At Nationwide Children's Hospital | Hmgb1 protein derivatives for the removal of biofilms |
| CA3183196A1 (en) * | 2020-07-07 | 2022-01-13 | Steven D. Goodman | Combination therapies for the treatment and prevention of biofilms |
| EP4615483A2 (en) * | 2022-11-11 | 2025-09-17 | Research Institute at Nationwide Children's Hospital | Compositions and methods for treating biofilms and neutrophil extracellular trap formation |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DE229046T1 (de) | 1985-03-30 | 1987-12-17 | Marc Genf/Geneve Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5686073A (en) | 1990-05-23 | 1997-11-11 | The University Of Iowa Research Foundation | Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein |
| US5580737A (en) | 1990-06-11 | 1996-12-03 | Nexstar Pharmaceuticals, Inc. | High-affinity nucleic acid ligands that discriminate between theophylline and caffeine |
| US5543293A (en) | 1990-06-11 | 1996-08-06 | Nexstar Pharmaceuticals, Inc. | DNA ligands of thrombin |
| US5503978A (en) | 1990-06-11 | 1996-04-02 | University Research Corporation | Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| ES2196002T3 (es) | 1991-07-25 | 2003-12-16 | Idec Pharma Corp | Anticuerpos recombinantes para terapia humana. |
| RU2212899C2 (ru) | 1991-09-13 | 2003-09-27 | Чирон Корпорейшн | Hcv иммунореактивные полипептидные композиции |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| EP0571613B1 (en) | 1991-12-13 | 2003-09-17 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5455338A (en) | 1993-11-05 | 1995-10-03 | Zymogenetics, Inc. | DNA encoding novel human kunitz-type inhibitors and methods relating thereto |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5631146A (en) | 1995-01-19 | 1997-05-20 | The General Hospital Corporation | DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof |
| US20050131222A1 (en) | 1995-04-21 | 2005-06-16 | Human Genome Sciences, Inc. | Nucleotide sequence of the haemophilus influenzae Rd genome, fragments thereof, and uses thereof |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US6709659B1 (en) | 1996-08-02 | 2004-03-23 | Zymogenetics, Inc. | Antibodies that bind testis-specific insulin homolog polypeptides |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| ES2230848T3 (es) | 1998-04-28 | 2005-05-01 | Smithkline Beecham Corporation | Anticuerpos monoclonales con inmunogenicidad reducida. |
| US6322788B1 (en) | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| US20020132753A1 (en) | 2000-01-31 | 2002-09-19 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| ATE549347T1 (de) | 2000-09-08 | 2012-03-15 | Schering Corp | Gene von säugetiere, und damit verbundene reagentien, methoden |
| WO2004001058A2 (en) | 2001-05-04 | 2003-12-31 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| CN100447154C (zh) | 2001-05-15 | 2008-12-31 | 费因斯坦医学研究学院 | 利用hmg片段作为抗炎症试剂 |
| AU2002328203C1 (en) | 2001-08-24 | 2009-01-08 | Migenix Inc. | Antimicrobial and anti-inflammatory peptides |
| ITMI20011986A1 (it) | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
| US20030099602A1 (en) | 2001-10-25 | 2003-05-29 | Levin Gilbert V. | D-tagatose as an anti-biofilm agent |
| US20060057160A1 (en) | 2002-08-02 | 2006-03-16 | Ralph Biemans | Vaccine composition |
| JP2006510619A (ja) | 2002-11-20 | 2006-03-30 | クリティカル セラピューティクス，インコーポレイテッド | 抗炎症剤としてのｈｍｇｂ断片の使用 |
| US20060121047A1 (en) | 2002-11-20 | 2006-06-08 | Tracey Kevin J | Use of hmgb polypetides for increasing immune responses |
| WO2004061456A2 (de) | 2003-01-03 | 2004-07-22 | Alcedo Biotech Gmbh | Verwendungen von hmgb, hmgn, hmga proteinen |
| US7297340B2 (en) | 2003-01-07 | 2007-11-20 | University Of Iowa Research Foundation | Vaccine and method for preventing biofilm formation |
| WO2004072094A2 (en) | 2003-02-14 | 2004-08-26 | Fondazione Centro San Raffaele Del Monte Tabor | Hmgb1 modulator binding domain |
| CA2796381A1 (en) | 2003-03-06 | 2004-09-16 | Children's Hospital, Inc. | Genes of an otitis media isolate of nontypeable haemophilus influenzae |
| WO2005025604A2 (en) | 2003-09-10 | 2005-03-24 | The General Hospital Corporation | Use of hmgb and hmgb fragments to decrease specific immune response |
| US20090029929A1 (en) | 2004-03-26 | 2009-01-29 | Locomogene, Inc. | Decoy Nucleic Acid to Synoviolin Gene Promoter |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| US20080305120A1 (en) | 2004-06-17 | 2008-12-11 | Medimmune, Inc. | Immunogenic Compositions Comprising Hmgb 1 Polypeptides |
| US20060030539A1 (en) | 2004-08-06 | 2006-02-09 | National Jewish Medical And Research Center | Product and process for inhibition of biofilm development |
| WO2007001422A2 (en) | 2004-10-22 | 2007-01-04 | Medimmune, Inc. | High affinity antibodies against hmgb1 and methods of use thereof |
| AU2005325801A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| US7119179B1 (en) | 2005-03-21 | 2006-10-10 | Los Alamos National Security, Llc | Preparation of high nitrogen compound and materials therefrom |
| US20060228384A1 (en) | 2005-04-06 | 2006-10-12 | Sequoia Sciences, Inc. | Control of biofilm with a biofilm inhibitor |
| WO2006114805A2 (en) | 2005-04-28 | 2006-11-02 | Fondazione Centro San Raffaele Del Monte Tabor | Use of hmgb2 and hmgb3 proteins for medical applications |
| CA2631184A1 (en) | 2005-11-28 | 2007-05-31 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US20090264342A1 (en) | 2006-02-13 | 2009-10-22 | Trustees Of Boston University | Compositions and methods for antibiotic potentiation and drug discovery |
| CA2660668C (en) | 2006-08-21 | 2016-06-28 | The University Of British Columbia | Small cationic antimicrobial peptides |
| EP1980269A1 (en) | 2007-04-13 | 2008-10-15 | Katholieke Universiteit Leuven | Prevention of staphylococcus biofilm formation |
| CN103097399A (zh) | 2010-03-29 | 2013-05-08 | 南加利福尼亚大学 | 用于去除生物膜的组合物及方法 |
| EP2613797B1 (en) | 2010-09-09 | 2015-11-04 | University Of Southern California | Compositions and methods for the removal of biofilms |
| ES2661500T3 (es) | 2012-07-26 | 2018-04-02 | Ospedale San Raffaele S.R.L. | Variantes de HMGB1 y sus usos |
| ES2746971T3 (es) | 2013-06-13 | 2020-03-09 | Res Inst Nationwide Childrens Hospital | Composiciones y procedimientos para el tratamiento de infecciones por burkholderia |
| US9745366B2 (en) | 2013-09-23 | 2017-08-29 | University Of Southern California | Compositions and methods for the prevention of microbial infections |
| GB201508337D0 (en) * | 2015-05-15 | 2015-06-24 | Hmgbiotech S R L | Novel peptides |
| WO2018170178A1 (en) * | 2017-03-15 | 2018-09-20 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
| MX2020014006A (es) | 2018-06-29 | 2021-05-27 | Res Inst Nationwide Childrens Hospital | Composiciones y métodos para mediar la eps. |
| AU2019354829B2 (en) | 2018-10-05 | 2025-04-17 | Research Institute At Nationwide Children's Hospital | Hmgb1 protein derivatives for the removal of biofilms |
-
2018
- 2018-03-14 WO PCT/US2018/022508 patent/WO2018170178A1/en not_active Ceased
- 2018-03-14 JP JP2019550715A patent/JP7596069B2/ja active Active
- 2018-03-14 EP EP18718961.8A patent/EP3595445B1/en active Active
- 2018-03-14 US US16/492,582 patent/US11746136B2/en active Active
- 2018-03-14 CA CA3056088A patent/CA3056088A1/en active Pending
- 2018-03-14 AU AU2018236271A patent/AU2018236271B2/en active Active
-
2022
- 2022-12-05 JP JP2022194227A patent/JP2023014389A/ja active Pending
-
2025
- 2025-02-06 JP JP2025018512A patent/JP2025065351A/ja active Pending
- 2025-07-15 JP JP2025119036A patent/JP2025148518A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020513808A5 (https=) | ||
| Sojka et al. | Antibiofilm efficacy of honey and bee-derived defensin-1 on multispecies wound biofilm | |
| Gopal et al. | Synergistic effects and antibiofilm properties of chimeric peptides against multidrug-resistant Acinetobacter baumannii strains | |
| Koulenti et al. | Novel antibiotics for multidrug-resistant gram-positive microorganisms | |
| Ramírez-Estrada et al. | Pseudomonas aeruginosa ventilator-associated pneumonia management | |
| Coates et al. | Novel classes of antibiotics or more of the same? | |
| Brigante et al. | Emergence and spread of a multidrug-resistant Acinetobacter baumannii clone producing both the carbapenemase OXA-23 and the 16S rRNA methylase ArmA | |
| Scoffone et al. | Role of RND efflux pumps in drug resistance of cystic fibrosis pathogens | |
| CY1114621T1 (el) | Συνταγοποιηση εισπνευσιμης λυσινικης αζτρεοναμης για τη θεραπευτικη αγωγη και προληψη πνευμονικων βακτηριακων μολυνσεων | |
| Sebbane et al. | Antibiotic therapy of plague: a review | |
| Tanhaeian et al. | Generation of an engineered food-grade Lactococcus lactis strain for production of an antimicrobial peptide: in vitro and in silico evaluation | |
| Wuerth et al. | Synthetic host defense peptide IDR-1002 reduces inflammation in Pseudomonas aeruginosa lung infection | |
| JP2017510580A5 (https=) | ||
| DK1353647T3 (da) | Inhalerbar aztreonam til behandling og forebyggelse af bakterielle lungeinfektioner | |
| Allan et al. | Low concentrations of nitric oxide modulate Streptococcus pneumoniae biofilm metabolism and antibiotic tolerance | |
| JP2025065351A5 (https=) | ||
| JP2022504139A5 (https=) | ||
| D'Atanasio et al. | A New Acid-oxidizing Solution: Assessment of Its Role on Methicillin-resistant Staphylococcus aureus (MRSA) Biofilm Morphological Changes. | |
| MX2021013663A (es) | Composiciones y métodos para el tratamiento de las condiciones pulmonares relacionadas con biopeliculas. | |
| Song et al. | Pseudomonas aeruginosa two-component system CprRS regulates HigBA expression and bacterial cytotoxicity in response to LL-37 stress | |
| Rensch et al. | Analysis of triclosan-selected Salmonella enterica mutants of eight serovars revealed increased aminoglycoside susceptibility and reduced growth rates | |
| JP2015510883A5 (https=) | ||
| Saraiva et al. | Monoclonal antibody anti-PBP2a protects mice against MRSA (methicillin-resistant Staphylococcus aureus) infections | |
| JP2018523675A5 (https=) | ||
| JP2016520599A5 (https=) |